Engineered immune cells take on tough leukemia
NCT ID NCT03620058
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tests a new approach for adults with acute lymphoblastic leukemia that has not responded to chemotherapy. Researchers take a patient's own immune cells, modify them in the lab to recognize and attack cancer cells with CD22 and CD19 proteins, and infuse them back. The goal is to see if this treatment is safe and can shrink or eliminate the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- modified immune cells (CAR T-cells) targeting CD22 and CD19 proteins
- What this could lead to
- If successful, this could provide a new treatment option for adults with hard-to-treat acute lymphoblastic leukemia that has not responded to chemotherapy.
- What could go wrong
- This is an early phase 1 trial with only 23 participants, so results may not apply to everyone. Side effects like cytokine release syndrome are possible, and the treatment may not work for all patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania
Philadelphia, Pennsylvania, 19104, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can donor immune cells be engineered to fight blood cancer?
- Can a Chemo-Antibody combo beat a tough leukemia?
- Personalized chemo dosing may boost leukemia remission in kids
- Targeted drug aims to clear hidden leukemia before transplant
- Supercharged immune cells take aim at cancer and viruses in one shot
- Double-Pronged immune cells take aim at stubborn blood cancers